Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20592078 | 0.84 | HRH1 (0.52) | TAAR1HTR2AGSRGABBR2GABBR1 | |
| SCHEMBL3336779 | 0.79 | GSR (0.55) | GSRNPC1ADAM17KDM4EMAPT | |
| SCHEMBL266714 | 0.79 | LMNA (0.43) | GSRNPC1ADAM17KDM4EMAPT | |
| SCHEMBL27340252 | 0.79 | GSR (0.42) | TAAR1HTR2AGSRNPC1ADAM17 | |
| SCHEMBL5532878 | 0.79 | GSR (0.42) | TAAR1HTR2AGSRNPC1ADAM17 | |
| SCHEMBL3115677 | 0.79 | GSR (0.42) | TAAR1HTR2AGSRNPC1ADAM17 | |
| SCHEMBL8125002 | 0.79 | GSR (0.42) | TAAR1HTR2AGSRNPC1ADAM17 | |
| SCHEMBL11456232 | 0.79 | CA1 (0.39) | TAAR1HTR2AGSRNPC1ADAM17 | |
| SCHEMBL27653040 | 0.78 | LOXL2 (0.46) | TAAR1GSRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10474946 | 0.78 | CPA1 (0.47) | GSRSLC6A2SLC6A4SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1066 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350609-A1 | METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF | SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) | 2024-10-24 | — | — | US | claimed |
| EP-4450082-A1 | METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF | Serum Institute Of India Private Limited (IN) | 2024-10-23 | — | — | EP | claimed |
| CN-118806889-A | Method for improving adsorption of polysaccharide-protein conjugates and multivalent vaccine formulations obtained therefrom | 印度血清研究所私人有限公司 | 2024-10-22 | — | — | CN | claimed |
| US-20240293524-A1 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-09-05 | — | — | US | claimed |
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2023-05-04 | — | — | US | claimed |
| EP-4025246-A2 | IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF | Serum Institute Of India Private Limited (IN) | 2022-07-13 | — | — | EP | claimed |
| CN-114728053-A | Immunogenic compositions against intestinal disease and process for preparing same | 印度血清研究所私人有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-20220008529-A1 | MULTI-FUNCTIONALIZED noMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-01-13 | — | — | US | claimed |
| EP-3799883-A1 | NOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GlaxoSmithKline Biologicals S.A. (BE) | 2021-04-07 | — | — | EP | claimed |
| WO-2021044436-A2 | IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF | SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) | 2021-03-11 | — | — | WO | claimed |
| WO-2018096013-A1 | nOMV-ANTIGEN CONJUGATES AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2018-05-31 | — | — | WO | claimed |
| CN-104519910-B | Adjuvanted formulations of streptococcus pneumoniae antigens | 诺华股份有限公司 | 2017-05-03 | — | — | CN | claimed |
| WO-2017067964-A1 | P. AERUGINOSA PCRV-LINKED ANTIGEN VACCINES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2017-04-27 | — | — | WO | claimed |
| CN-104519910-A | Adjuvanted formulations of streptococcus pneumoniae antigens | NOVARTIS AG | 2015-04-15 | — | — | CN | claimed |
| EP-2822586-A1 | ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE ANTIGENS | Novartis AG (CH) | 2015-01-14 | — | — | EP | claimed |
| WO-2013131983-A1 | ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE ANTIGENS | NOVARTIS AG (CH) | 2013-09-12 | — | — | WO | claimed |
| EP-2254890-A1 | PROCESS FOR THE DIASTEREOISOMERIC RESOLUTION OF 5-METHYLTETRAHYDROFOLIC ACID | Gnosis S.p.A. (IT) | 2010-12-01 | — | — | EP | claimed |
| WO-2009103333-A1 | PROCESS FOR THE DIASTEREOISOMERIC RESOLUTION OF 5-METHYLTETRAHYDROFOLIC ACID | GNOSIS S.P.A. (IT) | 2009-08-27 | — | — | WO | claimed |
| EP-1476197-A2 | SYNTHESIS OF LIPOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION FOLLOWING REMOVAL OF THE GLYCOSIDIC PHOSPHATE RESIDUE | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2004-11-17 | — | — | EP | claimed |
| WO-2003070282-A2 | SYNTHESIS OF LIPOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION FOLLOWING REMOVAL OF THE GLYCOSIDIC PHOSPHATE RESIDUE | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2003-08-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | VAPB, CD14, CHMP4B | TAAR1 4451/4885HTR2A 4844/4885GSR 2919/4885 |
| US-20240350609-A1 | METHODS FOR IMPROVING THE ADSORPTION OF POLYSACCHARIDE-PROTEIN CONJUGATES AND MULTIVALENT VACCINE FORMULATION OBTAINED THEREOF | DDOST, CD14, STT3B | TAAR1 4881/4885HTR2A 3282/4885GSR 3963/4885 |
| US-20240293524-A1 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | CD14, VAPB, CHMP4B | TAAR1 4193/4885HTR2A 4854/4885GSR 2728/4885 |
| US-20220008529-A1 | MULTI-FUNCTIONALIZED noMV CONJUGATES | CD14, CHMP4B, VAPB | TAAR1 4039/4885HTR2A 4860/4885GSR 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.